<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788840</url>
  </required_header>
  <id_info>
    <org_study_id>EC/2008/14/FHMS</org_study_id>
    <nct_id>NCT00788840</nct_id>
  </id_info>
  <brief_title>Detemir Energy Expenditure Study</brief_title>
  <acronym>DEES</acronym>
  <official_title>A 24-Week, National, Single-Centre, Open-Labelled, Randomised, Parallel-Group Trial Comparing Energy Expenditure With Insulin Detemir Versus NPH Insulin Using a Basal-Bolus Regimen With Insulin Aspart as the Mealtime Insulin in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Surrey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Surrey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study designed to compare the effects of 2 long-acting insulins, detemir and
      insulatard, on energy expenditure,weight, fat composition, gut hormone profiles, glycaemic
      control and fat and muscle gene expression over a 6 month period.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight change</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Energy Expenditure</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat composition</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat &amp; muscle gene expression</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycaemic control</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1. Insulatard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Detemir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulatard</intervention_name>
    <description>Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.</description>
    <arm_group_label>1. Insulatard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Detemir</intervention_name>
    <description>Detemir insulin used as long-acting insulin in treatment phase of study.</description>
    <arm_group_label>2. Detemir</arm_group_label>
    <other_name>Levemir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetes

          2. Treated with metformin

          3. Already on treatment with a long-acting or intermediate insulin.

          4. Over 18 years of age,

          5. HbA1c &gt; 7.0%

          6. BMI 27-40

          7. Able and willing to perform self-blood glucose monitoring.

          8. Able and willing to maintain consistent eating habits throughout the entire trial
             period.

          9. Able and willing to maintain consistent physical activity level during the entire
             trial period

        Exclusion Criteria:

          1. Patients on sulphonylureas or thiazolidinediones

          2. Proliferative retinopathy that has required acute treatment within the last six
             months.

          3. Impaired hepatic or renal functions.

          4. Cardiac problems.

          5. Uncontrolled hypertension (treated or untreated).

          6. Mental incapacity, unwillingness or a language barrier precluding adequate
             understanding or co-operation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Russell-Jones, MB BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Surrey</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Sheldon, MB BS</last_name>
    <phone>01483571122</phone>
    <phone_ext>2405</phone_ext>
    <email>benjamin.sheldon@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedar Centre, Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Sheldon, MB BS</last_name>
      <phone>01483571122</phone>
      <phone_ext>2405</phone_ext>
      <email>benjamin.sheldon@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Benjamin Sheldon, MB BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2008</study_first_submitted>
  <study_first_submitted_qc>November 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <last_update_submitted>November 10, 2008</last_update_submitted>
  <last_update_submitted_qc>November 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Professor David Russell-Jones</name_title>
    <organization>Cedar Centre, Royal Surrey County Hospital, Guildford, UK GU2 7XX</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

